- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Collaborators
- Suppliers
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- Research centres
- People
- Alistair Brown
- Anne-Laure Puaux
- Assoc Prof Joanna Groom
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Ethan Goddard-Borger
- Associate Professor Gemma Kelly
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor John Wentworth
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Kelly Rogers
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Melissa Call
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Shalin Naik
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Tracy Putoczki
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Belinda Phipson
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gwo Yaw Ho
- Dr Hamish King
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Jim Whittle
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Nadia Davidson
- Dr Nadia Kershaw
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Rory Bowden
- Dr Samir Taoudi
- Dr Sarah Best
- Dr Saskia Freytag
- Dr Shabih Shakeel
- Dr Sheau Wen Lok
- Dr Stephin Vervoort
- Dr Yunshun Chen
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor Daniel Gray
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor James McCarthy
- Professor James Murphy
- Professor Jane Visvader
- Professor Jeanne Tie
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leanne Robinson
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marnie Blewitt
- Professor Matthew Ritchie
- Professor Melanie Bahlo
- Professor Melissa Davis
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Czabotar
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Sandra Nicholson
- Professor Sant-Rayn Pasricha
- Professor Seth Masters
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Papenfuss
- Professor Wai-Hong Tham
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Clinician-scientist training
- Undergraduate
- Student research projects
- A multi-pronged approach to targeting myeloproliferative neoplasms
- A new paradigm of machine learning-based structural variant detection
- A whole lot of junk or a treasure trove of discovery?
- Advanced imaging interrogation of pathogen induced NETosis
- Analysing the metabolic interactions in brain cancer
- Atopic dermatitis causes and treatments
- Boosting the efficacy of immunotherapy in lung cancer
- Building a cell history recorder using synthetic biology for longitudinal patient monitoring
- Characterisation of malaria parasite proteins exported into infected liver cells
- Deciphering the heterogeneity of the tissue microenvironment by multiplexed 3D imaging
- Defining the mechanisms of thymic involution and regeneration
- Delineating the molecular and cellular origins of liver cancer to identify therapeutic targets
- Developing computational methods for spatial transcriptomics data
- Developing drugs to block malaria transmission
- Developing models for prevention of hereditary ovarian cancer
- Developing statistical frameworks for analysing next generation sequencing data
- Development and mechanism of action of novel antimalarials
- Development of novel RNA sequencing protocols for gene expression analysis
- Discoveries in red blood cell production and function
- Discovering epigenetic silencing mechanisms in female stem cells
- Discovery and targeting of novel regulators of transcription
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Dissecting mechanisms of cytokine signalling
- Doublecortin-like kinases, drug targets in cancer and neurological disorders
- Epigenetic biomarkers of tuberculosis infection
- Epigenetics – genome wide multiplexed single-cell CUT&Tag assay development
- Exploiting cell death pathways in regulatory T cells for cancer immunotherapy
- Exploiting the cell death pathway to fight Schistosomiasis
- Finding treatments for chromatin disorders of intellectual disability
- Functional epigenomics in human B cells
- How do nutrition interventions and interruption of malaria infection influence development of immunity in sub-Saharan African children?
- Human lung protective immunity to tuberculosis
- Improving therapy in glioblastoma multiforme by activating complimentary programmed cell death pathways
- Innovating novel diagnostic tools for infectious disease control
- Integrative analysis of single cell RNAseq and ATAC-seq data
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigation of a novel cell death protein
- Malaria: going bananas for sex
- Mapping spatial variation in gene and transcript expression across tissues
- Mechanisms of Wnt secretion and transport
- Multi-modal computational investigation of single-cell communication in metastatic cancer
- Nanoparticle delivery of antibody mRNA into cells to treat liver diseases
- Naturally acquired immune response to malaria parasites
- Organoid-based discovery of new drug combinations for bowel cancer
- Organoid-based precision medicine approaches for oral cancer
- Removal of tissue contaminations from RNA-seq data
- Reversing antimalarial resistance in human malaria parasites
- Role of glycosylation in malaria parasite infection of liver cells, red blood cells and mosquitoes
- Screening for novel genetic causes of primary immunodeficiency
- Single-cell ATAC CRISPR screening – Illuminate chromatin accessibility changes in genome wide CRISPR screens
- Spatial single-cell CRISPR screening – All in one screen: Where? Who? What?
- Statistical analysis of single-cell multi-omics data
- Structural and functional analysis of epigenetic multi-protein complexes in genome regulation
- Structural basing for Wnt acylation
- Structure, dynamics and impact of extra-chromosomal DNA in cancer
- Targeted deletion of disease-causing T cells
- Targeting cell death pathways in tissue Tregs to treat inflammatory diseases
- The cellular and molecular calculation of life and death in lymphocyte regulation
- The role of hypoxia in cell death and inflammation
- The role of ribosylation in co-ordinating cell death and inflammation
- Understanding Plasmodium falciparum invasion of red blood cells
- Understanding cellular-cross talk within a tumour microenvironment
- Understanding the genetics of neutrophil maturation
- Understanding the roles of E3 ubiquitin ligases in health and disease
- Unveiling the heterogeneity of small cell lung cancer
- Using combination immunotherapy to tackle heterogeneous brain tumours
- Using intravital microscopy for immunotherapy against brain tumours
- Using nanobodies to understand malaria invasion and transmission
- Using structural biology to understand programmed cell death
- Validation and application of serological markers of previous exposure to malaria
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Ashley Weir
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jasmine Rou
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Krishneel Prasa
- Lilly Backshell
- Malvika Kharbanda
- Megan Kent
- Naomi Jones
- Pailene Lim
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Sophie Collard
- Wayne Cawthorne
- Wil Lehmann
- Yanxiang Meng
- Zhong Yan Gan
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- Learning Hub
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A generous vision for impactful medical research
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Philanthropy through the power of sisterhood
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- Donors
- WEHI.TV
Cell signalling

Cells in our body work together and respond to changes in their environment. Many proteins are involved in transmitting signals within and between cells. Disruptions to this signalling is the cause of many diseases.
Our research into cell signalling aims to understand how different signals are transmitted, and their relevance to disease.
Our cell signalling research
Our researchers are investigating cell signalling in healthy cells, to understand what goes wrong to cause disease.
Particular foci of our research are:
- Investigating proteins that enable cell signalling, and how these signals are switched off.
- Defining the cell signalling pathways that trigger cell death and inflammation.
- Understanding how cell signalling pathways are subverted in diseases such as cancer, immune disorders and infections.
- Developing new treatments for disease that target key signalling molecules.
What is cell signalling?
Our bodies are composed of billions of cells that work together. Each cell responds to external signals from other cells, and from its environment. Cell signalling refers to the translation of an external signal into a cell’s response.
External signals can include:
- Direct contact with other cells or structures.
- Molecules that are secreted by other cells.
- Viral or bacterial infections.
- Nutrients, toxins or other molecules present in the environment.
Cells can have many different responses to external signals. A few examples are:
- Growing or dividing, or stopping division.
- Becoming activated to perform a specific function (e.g. to kill bacteria or infected cells).
- Dying, or staying alive.
- Moving or changing shape.
- Secreting a substance.
A particular signal may elicit different responses in different cell types. A cell’s response to a signal may also depend on other signals the cell receives, or has previously received.
Cell signalling molecules
Most cell signalling relies on pathways of molecules signalling to each other to bring about a response.
A ‘signalling cascade’ describes one molecule signalling to several molecules, which then signal to several more, and so on. This results in an amplified and complex response to one initial signal.
Receptors
Most external signals do not enter the cell themselves, but bind to the cell surface, usually via a protein called a receptor. These cell surface receptors often span the outer membrane of the cell.
Receptors are specific for one, or a few substances, called ‘ligands’. When the receptor is bound by its specific ligand, it changes shape in a way that is transmits the signal across the cell membrane – like turning a key in a lock moves the latch on the other side of the door.
Ligands
Ligands are substances that specifically bind receptors. Many ligands are proteins, and fit precisely into specific receptors. Hormones and cytokines are common ligands for signalling between cells.
Kinases
When a ligand binds a receptor, it triggers changes within the cell that influence other signalling molecules. Many signalling pathways involve proteins called kinases. Kinases can exist in ‘on’ and ‘off’ states of activation. In some cases, a binding of a ligand to a receptor will switch on (activate) a kinase.
When switched on, kinases attach a phosphate group onto other molecules, especially other proteins, changing how those proteins function. The proteins then have their own influences on other molecules.
Transcription factors
Many signalling pathways influence which genes are switched on in a cell. This effect can be mediated via changes to transcription factors, proteins that bind to specific DNA sequences in the genome. A transcription factor binding to a gene begins the process of copying it into its RNA form, allowing production of a particular protein.
Cell death signalling
Many signalling pathways in humans involve specialised proteins. Cell death signalling pathways are an example of this. In apoptotic cell death, various cellular stresses or a specific ligand binding to a ‘death receptor’ trigger changes within the cell that activate caspases, proteins that demolish the cell in a tightly controlled way.
Switching off signals
Cells in our body are constantly barraged with different signals from their environment. These signals may be short-lived and change rapidly. Cells need to be able to switch off signalling pathways as rapidly as they were switched on.
Proteins have evolved that act as feedback inhibitors and specifically terminate a cell signalling pathway. These proteins can switch off kinases or other signalling proteins, or initiate the destruction of proteins produced when the signalling pathway began.
The SOCS protein family was discovered by our researchers. These proteins specifically turn off many different types of signals. Our research has demonstrated that in the immune system SOCS proteins are especially important at restraining inflammatory signals. Without SOCS proteins, inflammatory signalling is prolonged and can cause tissue damage.
Cell signalling and disease
When cells do not respond appropriately to their environment, or do not work cooperatively with other cells, disease can result. Problems in cell signalling underlie many diseases. Some examples of disrupted cell signalling in disease include:
- Cancer cells have constant activation of signalling pathways instructing the cells to grow and divide. This often occurs because of changes (mutations) in receptors, protein kinases or transcription factors that keep the proteins an active state.
- Some immunodeficiencies occur because immune cells lack the receptors for ligands that instruct immune cells to divide and develop, or lack the specific kinases that transmit these signals.
- Many viruses, such as hepatitis B, produce proteins that interfere with the host cell’s signalling pathways in ways that suppress the immune system and enhance viral reproduction.
Targeting cell signalling
Cell signalling influences how cells behave in health and disease. Many medicines work by adjusting cell signalling pathways, often stifling a key signalling protein.
Some treatments for disease work by preventing a ligand binding to its receptor. Medications that block cytokine signalling between immune cells are in clinical use to treat inflammatory conditions such as rheumatoid arthritis.
Many new anti-cancer therapies target kinases that give cancer cells the signals to divide.
Our medicinal chemistry researchers are using three-dimensional structures of cell signalling proteins to develop small molecules that can specifically block the proteins’ function.
Researchers:
A signalling molecule called interleukin-11 is a potential new target for anti-cancer therapies
A landmark discovery about how insulin docks on cells could help in the development of improved types of insulin for treating both type 1 and type 2 diabetes.
Since their discovery by Professor Donald Metcalf and his colleagues, CSFs have helped millions of cancer patients to survive the damage to bone marrow caused by high-dose chemotherapy.